We next surveyed a collection of primary CCRCC specimens using an antibody directed against phosphorylated SMAD2 (pSMAD2), generally considered as a specific assessment of TGF-β signaling activity. The gene discussed is TGFB1; the disease is nonpapillary renal cell carcinoma.